Compare VRTX & SE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | SE |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Other Consumer Services |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8B | 58.7B |
| IPO Year | 2006 | 2017 |
| Metric | VRTX | SE |
|---|---|---|
| Price | $508.54 | $97.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 29 |
| Target Price | ★ $571.43 | $154.93 |
| AVG Volume (30 Days) | 992.3K | ★ 3.4M |
| Earning Date | 11-02-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 8.33 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.55 | $35.88 |
| Revenue Next Year | $9.78 | $22.88 |
| P/E Ratio | $60.29 | ★ $49.15 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $403.16 | $77.05 |
| 52 Week High | $560.25 | $171.09 |
| Indicator | VRTX | SE |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 43.59 |
| Support Level | $498.58 | $97.59 |
| Resistance Level | $531.78 | $98.89 |
| Average True Range (ATR) | 11.08 | 2.38 |
| MACD | -0.72 | 0.49 |
| Stochastic Oscillator | 60.73 | 70.59 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.